Business Wire

SPEEDX

Share
SpeeDx and MolGen Announce Partnership for COVID-19 Test Solution

SpeeDx Pty, Ltd. and MolGen announced the signing of an agreement to collaborate on supply and distribution of clinical diagnostics products and instrumentation across Europe and Asia Pacific. The partnership links specimen handling, nucleic acid extraction, assay set-up, amplification, and results reporting in a seamless integration of the companies technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005407/en/

“This partnership capitalises on the existing infrastructure of our two companies and the strength of our synergies,” said Colin Denver, SpeeDx CEO. “Our commitment to providing products and services that answer unmet clinical needs also extends to the pathology laboratories that are running our tests – in partnership with MolGen, we can address much of their workflow concerns and offer a more complete testing solution.”

Throughout the past year of COVID-19, in response to the increased demand for molecular testing workflow solutions, MolGen has developed a comprehensive offering including the PurePrep nucleic acid extraction portfolio, liquid handling instrumentation and other purpose-built automation to facilitate high-volume testing of SARS-CoV-2. SpeeDx complete the partnership with an initial offer of their CE-IVD SARS-CoV-2 test based on their proprietary Plex PCR® technology, allowing pathology laboratories a single point of contact to fulfil their testing needs.

“For MolGen, the collaboration with SpeeDx is a perfect example of combining the best of both worlds. Our DNA and RNA extraction solutions and automated workflow perfectly pair with SpeeDx diagnostic assay technology” said Maarten de Groot, MolGen CEO. “During the COVID pandemic adding the CE-IVD SARS-CoV-2 assay to our diagnostics portfolio is great opportunity to start our collaboration. And this is only the beginning of jointly building an innovative product portfolio”.

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin, Texas and London, UK, with distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com

About MolGen

MolGen is global total solution provider of innovative extraction DNA / RNA technology, system, products and kits for human and animal diagnostics, the agriculture and biotech industries which reduce hands-on time and increase productivity while maintaining high yields and reproducibility.

From sample to result, MolGen is challenging the status quo in molecular diagnostics by offering platform stand-alone systems and consumables. Highly customizable, MolGen’s portfolio offers the perfect workflow for our customers’ specific needs, being high-quality, adaptable and safe.

Due to travel restrictions Maarten de Groot, MolGen CEO and Colin Denver, SpeeDx CEO joined a virtual session to officially announce the collaboration that will combine Molgen liquid handling and purpose-built automation with SpeeDx COVID-19 diagnostic solutions - extending a full workflow offering to pathology laboratories.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 14:59:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac

Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 14:05:00 CEST | Press release

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for

Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model3.7.2025 12:02:00 CEST | Press release

The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702168211/en/ In 10-20% of tinnitus cases, the noise in the ear is so severe that it significantly impairs the quality of life of those affected. (Source: AI-generated) In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, th

H2SITE Secures EIC Accelerator Funding to Deploy a Flagship 1 TPD Ammonia Cracker Using Membrane Reactor Technology at a Port in North-West Europe3.7.2025 08:40:00 CEST | Press release

H2SITE has been awarded the EIC (European Innovation Council) Accelerator program for a project aimed at deploying a first-of-its-kind ammonia cracking unit capable of producing 1 ton of high-purity hydrogen per day. The system is based on H2SITE’s proprietary palladium-based membrane reactor technology, which enables the simultaneous catalytic decomposition of ammonia and selective hydrogen separation within a single unit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702142283/en/ Ammonia Cracker using Membrane Reactor Technology This breakthrough technology offers several compelling advantages over conventional ammonia cracking processes: Lowest Levelized Cost of Hydrogen (LCOH) from ammonia due to high efficiency and integrated operation Reduced energy consumption, operating at significantly lower temperatures (400–450 °C) than traditional cracking methods (typically 600–800 °C) High-purity hydrogen output, compliant

Curve Pay and Thales Join Forces to Securely Transform Digital Wallets on iPhone3.7.2025 08:00:00 CEST | Press release

This collaboration between Curve and Thales provides iOS users with greater control, flexibility, autonomy and digital-security for in-store contactless payments and digital wallets Curve, the ultimate digital wallet, today announced deepening its collaboration with Thales, the global leader in advanced technologies, delivering secure modern payment solutions for financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702696837/en/ Thales D1 Platform to power CURVE PAY (Photo: Thales) This partnership comes on the back of Curve launching Curve Pay on iOS, marking a watershed moment in mobile payments. This partnership is a significant step to reshaping everyday spending, allowing Curve customers to benefit from NFC payment directly in the Curve App for contactless payments in store for all end-users on iOS and Android. Curve Pay is underpinned by Thales’ D1 platform on iOS and Android in Europe which allows

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye